Information letter for healthcare professionals on the risks of teratogenicity and neuropsychiatric disorders associated with the use of retinoids

09.12.2021 1941 review

Інформаційний лист для спеціалістів системи охорони здоров’я щодо ризиків тератогенності та нейропсихічних порушень при застосуванні ретиноїдівPDF · 142 КБ

Завантажити

Information letter for healthcare professionals on the risks of teratogenicity and neuropsychiatric disorders associated with the use of retinoids

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter for healthcare professionals on the risks of teratogenicity and neuropsychiatric disorders associated with the use of retinoids

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration